Historical Overview and Current State of Art in Diagnosis and Treatment of Hodgkin's and Non-Hodgkin's Lymphoma

PET Clinics

Volumn 1, Issue 3, 2006, Pages 203-217

  de Vos, Sven ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33845194866     PISSN: 15568598     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cpet.2006.04.004     Document Type: Review

References (136)

1. Wilks S. Cases of enlargement of the lymphatic glands and spleen (or Hodgkin's disease), with remarks. Guys Hosp Rep 11 (1865) 56-67
2. Poston J.N. Positive Leu-MI immuno-histochemistry and diagnosis of the lymphoma cases described by Hodgkin in 1832. Appl Immunohistochem Mol Morphol 7 (1999) 6-8
3. Sternberg C. Ueber eine eigenartige unter dem Bilde der Pseudoleukaemie verlaufende Tuberculose des lymphatischen Apparates. Zeitschrift für Heilkunde 19 (1898) 21-90
4. Reed D. On the pathological changes in Hodgkin's disease, with especial reference to its relation to tuberculosis. Johns Hopkins Hosp Rep 10 (1902) 133-196
5. Küppers R. Molecular biology of Hodgkin's lymphoma, Hodgkin's disease and allied disorders (1947), Oxford University Press, New York
6. Lukes R.J., and Butler J.J. The pathology and nomenclature of Hodgkin's disease. Cancer Res 26 (1966) 1063-1083
7. Rosenberg S.A. Report of the committee on the staging of Hodgkin's disease. Cancer Res 26 (1966) 1310
8. Harris N.L., Jaffe E.S., Stein H., et al. A Revised European-American Classification of Lymphoid Neoplasms: a proposal from the International Lymphoma Study Group. Blood 84 (1994) 1361-1392
9. Virchow R. Weisses Blut. Neue Notizen aus dem Gebiet der Natur-fund Heilkunde. Floriep's Neue Notizen 36 (1845) 151
10. Bennett J.H. Case of hypertrophy of the spleen and liver in which death took place from supporation of the blood. Edinburgh Medical and Surgical Journal 64 (1845) 413-423
11. Virchow R. Die Krankenhaften Geschwulste. In: Hirschwald A, editor. Dreissig Vorlesungen gehalten wahrend des Wintersemestes (1862-1863) an der Universitat zu Berlin. Berlin; 1864. p. 728-38.
12. Brill N.E., Baehr G., and Rosenthal N. Generalized giant lymph follicle hyperplasia of lymph nodes and spleen; a hitherto undescribed type. Am J Med 84 (1925) 668-671
13. Symmers D. Follicular lymphadenopathy with splenomegaly. A newly recognized disease of the lymphatic system. Arch Pathol Lab Med 3 (1927) 816-820
14. Gall E.A., and Mallory T.B. Malignant lymphoma: a clinico-pathological survey of 618 cases. Am J Pathol 18 (1942) 381-429
15. Aisenberg A.C. Historical review of lymphomas. Br J Haematol 109 (2000) 466-476
16. Hicks E.B., Rappaport H., and Winter W.J. Follicular lymphoma; a re-evaluation of its position in the scheme of malignant lymphoma, based on a survey of 253 cases. Cancer 9 (1956) 792-821
17. Lennert K., Mohri N., Stein H., et al. Malignant lymphomas other than Hodgkin's disease. Histology, cytology, ultrastructure, immunology (1978), Springer-Verlag, New York
18. Lennert K. Origin of malignant lymphomas. [letter]. Lancet 2 (1974) 586
19. Stansfeld A.G., Diebold J., Noel H., et al. Updated Kiel classification for lymphomas. Lancet 1 (1988) 292-293
20. Lukes R.J., and Collins R.D. Immunologic characterization of human malignant lymphomas. Cancer 34 Suppl (1974) 1488-1503
21. Dorfman R.F. Classification of non-Hodgkin's lymphomas. [letter]. Lancet 1 (1974) 1295-1296
22. Dorfman R.F. Pathology of the non-Hodgkin's lymphomas: new classifications. Cancer Treat Rep 61 (1977) 945-951
23. Bennett M.H., Farrer-Brown G., and Henry K. Classification of non-Hodgkin's lymphomas. Lancet 2 (1974) 405-406
24. The Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer 49 (1982) 2112-2135
25. Jaffe E.S., Harris N.L., Stein H., et al. World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues (2001), IARC Press, Lyon (France)
26. Knowles II D.M., Dodson L.D., Raab R., et al. The application of monoclonal antibodies to the characterization and diagnosis of lymphoid neoplasms: a review of recent studies. Diagn Immunol 1 (1983) 142-149
27. Korsmeyer S.J., Hieter P.A., Ravetch J.V., et al. Developmental hierarchy of immunoglobulin gene rearrangements in human leukemic pre-B-cells. Proc Natl Acad Sci USA 78 (1981) 7096-7100
28. Aisenberg A.C., Krontiris T.G., Mak T.W., et al. Rearrangement of the gene for the beta chain of the T-cell receptor in T-cell chronic lymphocytic leukemia and related disorders. N Engl J Med 313 (1985) 529-533
29. Minden M.D., Toyonaga B., Ha K., et al. Somatic rearrangement of T-cell antigen receptor gene in human T-cell malignancies. Proc Natl Acad Sci USA 82 (1985) 1224-1227
30. Waldmann T.A., Davis M.M., Bongiovanni S.K., et al. Rearrangements of genes for the antigen receptor on T cells as markers of lineage and clonality in human lymphoid neoplasms. N Engl J Med 313 (1985) 776-783
31. Burkitt D. Burkitt's lymphoma. JAMA 222 (1972) 1164
32. Epstein M.A., Achong B.G., and Barr Y.M. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet 15 (1964) 702-703
33. de The G. The etiology of Burkitt's lymphoma and the history of the shaken dogmas. Blood Cells 19 (1993) 667-673 [discussion: 674-5]
34. Willemze R., Jaffe E.S., Burg G., et al. WHO-EORTC classification for cutaneous lymphomas. Blood 105 (2005) 3768-3785
35. Alizadeh A.A., Eisen M.B., Davis R.E., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403 (2000) 503-511
36. Staudt L.M., and Dave S. The biology of human lymphoid malignancies revealed by gene expression profiling. Adv Immunol 87 (2005) 163-208
37. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329 (1993) 987-994
38. Solal-Celigny P., Roy P., Colombat P., et al. Follicular Lymphoma International Prognostic Index. Blood 104 (2004) 1258-1265
39. Pusey W.A. Cases of sarcoma and of Hodgkin's disease treated by exposure to X-rays: a preliminary report. JAMA 38 (1902) 166-169
40. Gilbert R. Radiotherapy in Hodgkin's disease (malignant lymphogranulomatosis). Anatomic and clinical foundations; governing principles; results. AJR Am J Roentgenol 41 (1939) 198-241
41. Kaplan H.S. The radical radiotherapy of regionally localized Hodgkin's disease. Radiology 78 (1962) 553-561
42. Goodman L.S., Wintrobe M.M., Dameshek W., et al. Role of chance observation in chemotherapy. Ann NY Acad Sci 76 (1958) 882-894
43. Warwick O.H., Alison R.E., and Darte J.M. Clinical experience vinblastine sulfate. Can Med Assoc J 85 (1961) 579-583
44. Mathe G., Schweisguth O., Schneider M., et al. Methyl-hydrazine in treatment of Hodgkin's disease and various forms of haematosarcoma and leukaemia. Lancet 12 (1963) 1077-1080
45. Blum R.H., Carter S.K., and Agre K. A clinical review of bleomycin-a new antineoplastic agent. Cancer 31 (1973) 903-914
46. Lessner H.E. BCNU (1, 3,bis(B-chloroethyl)-1-nitrosourea. Effects on advanced Hodgkin's disease and other neoplasia. Cancer 22 (1968) 451-456
47. Gottlieb J.A., Gutterman J.U., McCredie J.B., et al. Chemotherapy of malignant lymphoma with adriamycin. Cancer Res 33 (1973) 3024-3028
48. Issell B.F., Rudolph A.R., and Louie A. Etoposide: current status and new developments (1984), Academic Press, New York
49. Lacher M.J., and Durant J.R. Combined vinblastine and chlorambucil therapy of Hodgkin's disease. Ann Intern Med 62 (1965) 468-476
50. Devita Jr. V.T., Serpick A.A., and Carbone P.P. Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med 73 (1970) 881-895
51. Bonadonna G., and Santoro A. Evolution in the treatment strategy of Hodgkin's disease. Adv Cancer Res 36 (1982) 257-293
52. Canellos G.P., Anderson J.R., Propert J.K., et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327 (1992) 1478-1484
53. Duggan D.B., Petroni G.R., Johnson J.L., et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol 21 (2003) 607-614
54. DeVita Jr. V.T., Canellos G.P., Chabner B., et al. Advanced diffuse histiocytic lymphoma, a potentially curable disease. Lancet 1 (1975) 248-250
55. McKelvey E.M., Gottlieb J.A., Wilson H.E., et al. Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphoma. Cancer 38 (1976) 1484-1493
56. Goldie J.H., Coldman A.J., and Gudauskas G.A. Rationale for the use of alternating non-cross-resistant chemotherapy. Cancer Treat Rep 66 (1982) 439-449
57. DeVita Jr. V.T., Hubbard S.M., and Longo D.L. The chemotherapy of lymphomas: looking back, moving forward-the Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 47 (1987) 5810-5824
58. Fisher R.I., Gaynor E.R., Dahlberg S., et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328 (1993) 1002-1006
59. Coiffier B., Lepage E., Briere J., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346 (2002) 235-242
60. Philip T., Guglielmi C., Hagenbeek A., et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333 (1995) 1540-1545
61. Lazarus H.M., Rowlings P.A., Zhang M.J., et al. Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 17 (1999) 534-545
62. Hans C.P., Weisenburger D.D., Vose J.M., et al. A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. Blood 101 (2003) 2363-2367
63. Bloomfield C.D., Arthur D.C., Frizzera G., et al. Nonrandom chromosome abnormalities in lymphoma. Cancer Res 43 (1983) 2975-2984
64. Rowley J.D. Chromosome studies in the non-Hodgkin's lymphomas: the role of the 14;18 translocation. J Clin Oncol 6 (1988) 919-925
65. Korsmeyer S.J. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 80 (1992) 879-886
66. Longo D.L. What's the deal with follicular lymphomas?. J Clin Oncol 11 (1993) 202-208
67. Horning S.J., and Rosenberg S.A. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 311 (1984) 1471-1475
68. Krikorian J.G., Portlock C.S., Cooney P., et al. Spontaneous regression of non-Hodgkin's lymphoma: a report of nine cases. Cancer 46 (1980) 2093-2099
69. Ardeshna K.M., Smith P., Norton A., et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 362 (2003) 516-522
70. Mac Manus M.P., and Hoppe R.T. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 14 (1996) 1282-1290
71. Wilder R.B., Jones D., Tucker S.L., et al. Long-term results with radiotherapy for stage I-II follicular lymphomas. Int J Radiat Oncol Biol Phys 51 (2001) 1219-1227
72. Peterson B.A., Petroni G.R., Frizzera G., et al. Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the Cancer and Leukemia Group B. J Clin Oncol 21 (2003) 5-15
73. Glick J.H., Barnes J.M., Ezdinli E.Z., et al. Nodular mixed lymphoma: results of a randomized trial failing to confirm prolonged disease-free survival with COPP chemotherapy. Blood 58 (1981) 920-925
74. Johnson P.W., Rohatiner A.Z., Whelan J.S., et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol 13 (1995) 140-147
75. Cartron G., Watier H., Golay J., et al. From the bench to the bedside: ways to improve rituximab efficacy. Blood 104 (2004) 2635-2642
76. Schulz H., Skoetz N., Bohlius J., et al. Does combined immunochemotherapy with the monoclonal antibody rituximab improve overall survival in the treatment of patients with indolent non-Hodgkin lymphoma? Preliminary results of a comprehensive meta-analysis. [abstract]. Blood 106 (2005) 136
77. Colombat P., Salles G., Brousse N., et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 97 (2001) 101-106
78. Hainsworth J.D., Litchy S., Burris III H.A., et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. J Clin Oncol 20 (2002) 4261-4267
79. Witzig T.E., Vukov A.M., Habermann T.M., et al. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group. J Clin Oncol 23 (2005) 1103-1108
80. Davis T.A., Grillo-Lopez A.J., White C.A., et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 18 (2000) 3135-3143
81. Hochster H.S., Weller E., Ryan T., et al. Results of E 1496: a phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL). [abstract]. Proc Am Soc Clin Oncol 23 (2004) 556
82. Ghielmini M., Schmitz S.F., Cogliatti S.B., et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule. Blood 103 (2004) 4416-4423
83. Hainswoth J., Litchy S., and Greco F.A. Scheduled rituximab maintenance therapy versus rituximab retreatment at progression in patients with indolent non-Hodgkin's lymphoma (NHL) responding to single-agent rituximab: a randomized trial of the Minnie Pearl Cancer Research Network. [abstract]. Blood 102 (2003) 69
84. Forstpointner R., Dreyling M., Repp R., et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 104 (2004) 3064-3071
85. Czuczman M.S., Grillo-Lopez A.J., White C.A., et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17 (1999) 268-276
86. Czuczman M.S., Weaver R., Alkuzweny B., et al. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 22 (2004) 4711-4716
87. Hiddemann W., Kneba M., Dreyling M., et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106 (2005) 3725-3732
88. Friedberg J.W., Neuberg D., Gribben J.G., et al. Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. Br J Haematol 117 (2002) 828-834
89. Leonard J.P., Siegel J.A., and Goldsmith S.J. Comparative physical and pharmacologic characteristics of iodine-131 and yttrium-90: implications for radioimmunotherapy for patients with non-Hodgkin's lymphoma. Cancer Invest 21 (2003) 241-252
90. Witzig T.E., White C.A., Wiseman G.A., et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 17 (1999) 3793-3803
91. Kaminski M.S., Tuck M., Estes J., et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 352 (2005) 441-449
92. Kwak L.W., Campbell M.J., Czerwinski D.J., et al. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 327 (1992) 1209-1215
93. Bendandi M., Gocke C.D., Kobrin C.B., et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 5 (1999) 1171-1177
94. Freedman A.S., Neuberg D., Mauch P., et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 94 (1999) 3325-3333
95. Apostolidis J., Gupta R.K., Grenzelias D., et al. High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up. J Clin Oncol 18 (2000) 527-536
96. Horning S.J., Negrin R.S., Hoppe R.T., et al. High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial. Blood 97 (2001) 404-409
97. Lenz G., Dreyling M., Schiegnitz E., et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 104 (2004) 2667-2674
98. Sebban C.B.C., and Brousse N. Comparison of CHVP+ interferon with CHOP followed by autologous stem cell transplantation with a TBI conditioning regimen in untreated patients with high tumor burden follicular lymphoma: results of the randomized GELF 94 trial (G.E.L.A. Study Group). Blood 102 (2003) 104
99. Micallef I.N., Lillington D.M., Apostolidis J., et al. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol 18 (2000) 947-955
100. Schouten H.C., Qian W., Kvaloy S., et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol 21 (2003) 3918-3927
101. Deconinck E., Foussard C., Milpied N., et al. High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. Blood 105 (2005) 3817-3823
102. van Besien K., Loberiza Jr. F.R., Bajorunaite R., et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 102 (2003) 3521-3529
103. Toze C.L., Barnett M.J., Connors J.M., et al. Long-term disease-free survival of patients with advanced follicular lymphoma after allogeneic bone marrow transplantation. Br J Haematol 127 (2004) 311-321
104. van Besien K.W., Khouri I.F., Giralt S.A., et al. Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management. J Clin Oncol 13 (1995) 1096-1102
105. Friedberg J.W., Neuberg D., Gribben J.G., et al. Autologous bone marrow transplantation after histologic transformation of indolent B cell malignancies. Biol Blood Marrow Transpl 5 (1999) 262-268
106. Rosenwald A., Wright G., Chan W.C., et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346 (2002) 1937-1947
107. Miller T.P., Dahlberg S., Cassady J.R., et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 339 (1998) 21-26
108. Horning S.J., Weller E., Kim K., et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol 22 (2004) 3032-3038
109. Pfreundschuh M.G., Ho A., Wolf M., et al. Treatment results of CHOP-21, CHOEP-21, MACOP-B and PMitCEBO with and without RITUXIMAB in young good-prognosis patients with aggressive lymphomas: RITUXIMAB as an "EQUALIZER" in the MInT (MABTHERA INTERNATIONAL TRIAL GROUP) study. [abstract]. Proc Am Soc Clin Oncol (2005) 257
110. Greb A., Schiefer D.H., Bohlius J., et al. High-dose chemotherapy with autologous stem cell support is not superior to conventional-dose chemotherapy in the first-line treatment of aggressive non-Hodgkin lymphoma-results of a comprehensive meta-analysis. [abstract]. Blood 104 (2004) 263
111. Wilson W.H., Gutierrez M., O'Connor P., et al. The role of rituximab and chemotherapy in aggressive B-cell lymphoma: a preliminary report of dose-adjusted EPOCH-R. Semin Oncol 29 Suppl 2 (2002) 41-47
112. Bertoni F., Zucca E., and Cotter F.E. Molecular basis of mantle cell lymphoma. Br J Haematol 124 (2004) 130-140
113. Kasamon Y.L., Jones R.J., Diehl L.F., et al. Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma. Biol Blood Marrow Transplant 11 (2005) 39-46
114. Lefrere F., Delmer A., Levy V., et al. Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: a matched pair analysis. Ann Oncol 15 (2004) 283-290
115. Mangel J., Leitch H.A., Connors J.M., et al. Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis. Ann Oncol 15 (2004) 283-290
116. Maris M.B., Sandmaier B.M., Storer B.E., et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 104 (2004) 3535-3542
117. Kouroukis C.T., Belch A., Crump M., et al. Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 21 (2003) 1740-1745
118. Goy A., Younes A., McLaughlin P., et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 23 (2005) 667-675
119. Kaufmann H., Raderer M., Wohrer S., et al. Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood 104 (2004) 2269-2271
120. Witzig T.E., Geyer S.M., Ghobrial I., et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 23 (2005) 5347-5356
121. Magrath I., Adde M., Shad A., et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 14 (1996) 925-934
122. Mead G.M., Sydes M.R., Walewski J., et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol 13 (2002) 1264-1274
123. Kanzler H., Kuppers R., Hansmann M.L., et al. Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med 184 (1996) 1495-1505
124. Lister T.A., Crowther D., Sutcliffe S.B., et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 7 (1989) 1630-1636
125. Hasenclever D., and Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 339 (1998) 1506-1514
126. Aisenberg A.C. Problems in Hodgkin's disease management. Blood 93 (1999) 761-779
127. Reis L.A.G., Kosary C.L., Hankey B.F., et al. SEER cancer statistics review, 1973-1995 (1998), National Cancer Institute, Bethesda (MD)
128. Hoppe R.T. Hodgkin's disease: complications of therapy and excess mortality. Ann Oncol 8 Suppl 1 (1997) 115-118
129. Connors J.M. Hodgkin's lymphoma: the hazards of success. J Clin Oncol 21 (2003) 3388-3390
130. Meyer R.M., Gospodarowicz M.K., Connors J.M., et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 23 (2005) 4634-4642
131. Loeffler M., Brosteanu O., Hasenclever D., et al. Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease. International Database on Hodgkin's Disease Overview Study Group. J Clin Oncol 16 (1998) 818-829
132. Horning S.J., Hoppe R.T., Breslin S., et al. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol 20 (2002) 630-637
133. Diehl V., Franklin J., Pfreundschuh M., et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 348 (2003) 2386-2395
134. Schmitz N., Pfistner B., Sextro M., et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 359 (2002) 2065-2071
135. Linch D.C., Winfield D., Goldstone A.H., et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 341 (1993) 1051-1054
136. Cheson B.D., Pfistner B., Juweid M.E., et al. Revised response criteria for malignant lymphomas from the members of the International Harmonization Project (IHP) of the Competence Network Malignant Lymphoma. [abstract]. Blood 105 (2005) 10a